Intercom was founded in 2011 by Eoghan McCabe, Des Traynor, Ciaran Lee, and David Barrett. Intercom has not officially endorsed a plan to participate in an IPO.

Intercom is a Conversational Relationship platform that helps businesses build better customer relationships through personalized, messenger-based experiences. Per Forge data, Intercom raised $240.8 million in funding over 8 rounds. Their latest funding was raised on Dec 1, 2020. Key investors include Social Capital, Kleiner Perkins, Bessemer Ventures, and Index Ventures.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Intercom, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Intercom

To invest in Intercom pre-IPO

Can you invest in Intercom pre-IPO?

Intercom is a privately held company and is not publicly traded, therefore investing in Intercom pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Intercom before it goes public?

You can seek to sell your shares in Intercom while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Intercom shares?

To determine the value of your Intercom shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Intercom shares. You can also learn more about how to sell your private shares before getting started.

Is Intercom a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Intercom potential IPO

Will Intercom go IPO?

Intercom has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Intercom’s IPO price?

The Intercom IPO price does not exist at this time, as Intercom is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Intercom register for Forge Markets, today.

When was Intercom founded?

Intercom was founded in 2011.

What is Intercom funding to date?

Intercom has raised $241.37MM to date.

Who are Intercom’s major investors?

Ashhill Pharma
Gv
Jason Fried
Bessemer Venture Partners
Freestyle Capital
Social+Capital Partnership
Kleiner Perkins
Founders Circle Capital
Iconiq Capital
Index Ventures (Uk)
Index Ventures
Iconiq Growth
Kernel
Stewart Butterfield
Evolution Vc Partners
Conor Stanley
Brandon Capital
Jack Dorsey
Venbio
Social Capital
David Sacks
Mark Zuckerberg
500 Global
Olive Tree Capital

Intercom Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/17/2018 Series D $125MM $xx.xx $1.27B Kleiner Perkins, GV, Bessemer Venture Partners, Index Ventures, Jack Dorsey, Mark Zuckerberg, Founders Circle Capital
Price per Share
$xx.xx
Shares Outstanding
2,692,058
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Kleiner Perkins, GV, Bessemer Venture Partners, Index Ventures, Jack Dorsey, Mark Zuckerberg, Founders Circle Capital
04/07/2016 Series C-1 $50.1MM $xx.xx $510.3MM Index Ventures (UK) , Social Capital, Bessemer Venture Partners, ICONIQ Capital, Stewart Butterfield, Jason Fried
Price per Share
$xx.xx
Shares Outstanding
2,293,050
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Index Ventures (UK) , Social Capital, Bessemer Venture Partners, ICONIQ Capital, Stewart Butterfield, Jason Fried
08/26/2015 Series C $35MM $xx.xx $290.71MM ICONIQ Capital , Social+Capital Partnership, Bessemer Venture Partners
Price per Share
$xx.xx
Shares Outstanding
2,565,644
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ICONIQ Capital , Social+Capital Partnership, Bessemer Venture Partners
01/22/2014 Series B $22.75MM $xx.xx $81.4MM Bessemer Venture Partners, Kernel, VenBio, Brandon Capital, AshHill Pharma
Price per Share
$xx.xx
Shares Outstanding
4,652,066
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bessemer Venture Partners, Kernel, VenBio, Brandon Capital, AshHill Pharma
06/19/2013 Series A $8.52MM $xx.xx $28.39MM Social+Capital Partnership, Freestyle Capital, Conor Stanley, David Sacks
Price per Share
$xx.xx
Shares Outstanding
4,503,050
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Social+Capital Partnership, Freestyle Capital, Conor Stanley, David Sacks
Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.